Literature DB >> 3146595

Effects of theophylline infusion on the growth hormone (GH) and prolactin response to GH-releasing hormone administration in acromegaly.

M Losa1, J Alba-Lopez, J Schopohl, S Sobiesczcyk, P G Chiodini, O A Müller, K von Werder.   

Abstract

Since theophylline has been shown to blunt the GH response to growth hormone-releasing hormone (GHRH) in normal subjects, we investigated whether the same effect of theophylline administration could be reproduced in patients with active acromegaly. Ten acromegalic patients received on two different days 100 micrograms GHRH iv alone and the same GHRH dose during a constant infusion of theophylline (3.56 mg/min), beginning 2 h before GHRH administration. In the whole group theophylline did not affect basal GH secretion significantly (from a mean of 44.6 +/- 14.4 at 0 min to 41.8 +/- 13.5 ng/ml at 120 min). However, the amount of GH released after GHRH stimulation was lower when theophylline was concomitantly infused (7525 +/- 3709 ng min/ml vs. 12038 +/- 6337 ng min/ml; p less than 0.05). The inhibitory effect of theophylline was not homogeneous, since either marked or minimal reductions of the GHRH-stimulated GH secretion occurred. Serum PRL levels increased after GHRH administration in 6 patients and theophylline infusion had no influence upon this response. Peak GHRH levels were not different in both studies (14.9 +/- 1.7 and 17.1 +/- 4.0 ng/ml, respectively). Free fatty acid levels rose progressively during theophylline administration (from 0.66 +/- 0.10 at 0 min to 1.04 +/- 0.10 mEq/l at 240 min) and were significantly higher than after GHRH stimulation alone from 180 min up to the end of the test. Our results demonstrate that in active acromegaly theophylline blunts the GH response to GHRH, though this effect is not uniformly seen in all patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146595     DOI: 10.1007/BF03350209

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  On the mechanism of action of theophylline and caffeine.

Authors:  B B Fredholm
Journal:  Acta Med Scand       Date:  1985

2.  Effect of aminophylline on the secretion of insulin, glucagon, luteinizing hormone and growth hormone in humans.

Authors:  J W Ensinck; R W Stoll; C C Gale; R J Santen; J L Touber; R H Williams
Journal:  J Clin Endocrinol Metab       Date:  1970-08       Impact factor: 5.958

3.  Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.

Authors:  M O Thorner; J Rivier; J Spiess; J L Borges; M L Vance; S R Bloom; A D Rogol; M J Cronin; D L Kaiser; W S Evans; J D Webster; R M MacLeod; W Vale
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

4.  Growth hormone releasing factor (hpGRF)-stimulation test in normal controls and acromegalic patients.

Authors:  K von Werder; O A Müller; R Hartl; M Losa; G K Stalla
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

5.  Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRH1-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men.

Authors:  G Sassolas; P Chatelain; R Cohen; J P Boissel; S Laporte; J Galleyrand; B Claustrat; A Elmcharfi; J A Chayvialle; H Cohen
Journal:  J Clin Endocrinol Metab       Date:  1984-10       Impact factor: 5.958

6.  Human pancreatic tumor growth hormone (GH) - releasing factor and cyclic adenosine 3',5'- monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide.

Authors:  M J Cronin; E L Hewlett; W S Evans; M O Thorner; A D Rogol
Journal:  Endocrinology       Date:  1984-03       Impact factor: 4.736

7.  Growth hormone responsiveness to human pancreatic growth hormone releasing factor in acromegaly: modulatory effects of basal hormone levels and of concomitant somatostatin administration.

Authors:  G F Pieters; A E Smals; A R Hermus; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Clin Endocrinol (Oxf)       Date:  1984-12       Impact factor: 3.478

8.  Somatocrinin (growth hormone releasing factor) in vitro bioactivity; Ca++ involvement, cAMP mediated action and additivity of effect with PGE2.

Authors:  P Brazeau; N Ling; F Esch; P Böhlen; C Mougin; R Guillemin
Journal:  Biochem Biophys Res Commun       Date:  1982-11-30       Impact factor: 3.575

9.  Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Endocrinol Metab       Date:  1985-05       Impact factor: 5.958

10.  The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man.

Authors:  T Imaki; T Shibasaki; K Shizume; A Masuda; M Hotta; Y Kiyosawa; K Jibiki; H Demura; T Tsushima; N Ling
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

View more
  1 in total

1.  Origin of the X-chromosome influences the development and treatment outcomes of Turner syndrome.

Authors:  Ying Zhang; Yongchen Yang; Pin Li; Sheng Guo
Journal:  PeerJ       Date:  2021-12-09       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.